UGT1A1 and colorectal carcinoma: Therefore, UGT1A1 promoter methylation and subsequent inhibition of UGT1A1-related metabolic pathways participate in the retention of active SN-38 in CRC, enhancing the therapeutic effect of irinotecan [112].